Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder

NCT00236379 is registered in ClinicalTrials.gov with Janssen, LP as lead sponsor.

NCT NCT00236379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00236379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder
Lead sponsor
Janssen, LP
Phase
Phase 4
Overall status
Completed
Start date
Not reported
Completion date
August 31, 2003
Enrollment
59 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, schizophrenia